Create It, Make It, Sell It: Chance Leonard and Dr. Sean Churchill on Building Medtech That Wins
Most medtech founders arrive with a great idea and real passion. What they usually lack is a clear view of how many stages, how much time and how much capital stand between that idea and patients. Closing that gap is the job of Genesis Innovation Group, and its two leaders have seen the climb from every side.
Dr. Sean Churchill worked as a professional engineer for three years to pay for medical school, then built a 21-year shoulder reconstruction practice outside Milwaukee. In 2004 he helped form a small implant company that won FDA clearance and was acquired by Tornier, which was acquired by Wright Medical, which was acquired by Stryker. Each time, he stayed on to design. Chance Leonard took a different path: a wrestler at the Air Force Academy and the University of Oklahoma, he spent nearly 15 years at Synthes, then led Stanmore Implants to a Stryker acquisition in just over three years. Two and a half years ago, Sean handed Chance the CEO role at Genesis. In this episode, they join Duane Mancini to talk about what it really takes to get a device from idea to exit.
Startup Speed Is a Competitive Advantage
Sean's first company moved fast. When engineers sent him drawings at night, he marked them up, and "by 8:00 in the morning they were changed." At a large company, he recalls, changing a screw length took seven signatures. When those same engineers called him after the acquisitions and asked to do it again, they formed Genesis: engineering, prototyping, clean rooms, IP and regulatory under one roof, built to keep working rather than to sell once and walk away.
Chance distills the work into three things every company must do with excellence: create a product, make a product and sell a product. Genesis's role, he says, is to act as a sherpa on Mount Everest, getting founders to the summit and, "most importantly, down safely." Sometimes that means changing the plan. One startup arrived with a product and a first indication; Genesis improved the device and steered it toward a different indication, and the result was "a significantly higher exit value."
Smart Money and the Right Feedback
Sean also leads cultivate(MD), an early-stage fund formed in 2017 that now counts about 175 limited partners, nearly half of them physicians. When a deal lands in a specialty he doesn't know, he asks the fund's specialists. That habit once saved him: three weeks into diligence on a gastroenterology device, the fund's gastroenterologists loved it but warned that GLP-1 drugs were about to shrink the procedures it served.
That is what Sean means by "smart money." cultivate(MD) takes a board seat in every investment and checks in with each CEO at least weekly. The two investments where it didn't hold a board seat both went south. And a founder who won't take advice is a red flag. Chance put the lesson in one word: humility. "You don't have to know every single answer," Sean told him early on, "but you at least got to ask for help."
Trust Is Built One Promise at a Time
Both men are Ironman athletes, and both see the same discipline in company building. "If you're not willing to sacrifice for what you want," Chance says, "what you want becomes the sacrifice." Trust, they agree, works the same way. In the operating room, Sean became known for exact time estimates: when he said a case had 37 minutes left, it did, and soon the next room was always ready. Chance calls it making deposits before you ever need a withdrawal.
Why This Matters
Early-stage medtech companies rarely fail for lack of passion. They fail on underestimated timelines, the wrong indication, unvetted vendors and advice that arrives too late. Genesis and cultivate(MD) show what changes when engineering, clinical insight and investor networks sit close to the founder and stay engaged from the first prototype to the exit.
For founders, the takeaways are practical: choose partners and investors who will work alongside you, test your indication against people who see the market every day, and treat asking for help as a strength.
What to Watch
cultivate(MD) has grown from a single seed fund backing only Genesis companies to five or six funds investing more broadly, so watch how its physician-heavy investor network shapes the companies it backs next. Watch too for how fast-moving GLP-1 drugs reshape the case for devices across obesity and metabolic care. And as large companies keep acquiring their way into new categories, development partners that move at startup speed may matter more than ever.
Catch the full episode here: https://www.projectmedtech.com/projectmedtechpodcast/episode/20ef71d1/episode-288-chance-leonard-dr-sean-churchill-genesis-innovation-group-create-it-make-it-sell-it-building-medtech-companies-that-win
Helpful Links
Thank you to our sponsors: Ward Law, Wheelhouse DMG, and JumpStart Inc.



Comments